Lumicks, which is developing single-molecule analysis technology based on research at Vrije Universiteit Amsterdam, has collected $93m.
Lumicks, a Netherlands-based single-molecule analysis technology spinout of Vrije Universiteit Amsterdam, has closed a $93m series D round backed by internet and telecommunications group SoftBank’s Vision Fund 2.
The round was co-led by Farallon Capital Management and Lauxera Capital Partners.
It also included funds and accounts advised by T Rowe Price, Parian Global Management, Pura Vida Investments, Irving Investors, existing backer Gilde Healthcare and unnamed members of Lumicks’ management team.
Founded in 2014, Lumicks is developing single-molecule analysis technology for molecular biology research and immunotherapy development.
Its tools include a microscopy system for the imaging of single-molecule interactions and another device for cell avidity analysis, which measures the strength of the interactions between immune cells and cancer cells.
The spinout’s technology is based on research conducted by professors Gijs Wuite, Erwin Peterman, Iddo Heller.
The majority of the funding will be used to expand…
